These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 30596395)
1. Detection of Anaplastic Lymphoma Kinase Gene Re-Arrangement in Non-Small Cell Lung Carcinoma in the Indian Population: Comparison of Techniques and Immunohistochemistry Clones. Shukla S; Pandey RK; Kant S; Garg R; Anand N; Kushwaha R; Malhotra KP; Srivastava A; Bhatt M; Husain N Turk Patoloji Derg; 2019; 35(1):36-45. PubMed ID: 30596395 [TBL] [Abstract][Full Text] [Related]
2. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275 [TBL] [Abstract][Full Text] [Related]
4. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance. Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243 [TBL] [Abstract][Full Text] [Related]
7. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics]. Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459 [TBL] [Abstract][Full Text] [Related]
10. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079 [TBL] [Abstract][Full Text] [Related]
11. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Thunnissen E; Lissenberg-Witte BI; van den Heuvel MM; Monkhorst K; Skov BG; Sørensen JB; Mellemgaard A; Dingemans AMC; Speel EJM; de Langen AJ; Hashemi SMS; Bahce I; van der Drift MA; Looijen-Salamon MG; Gosney J; Postmus PE; Samii SMS; Duplaquet F; Weynand B; Durando X; Penault-Llorca F; Finn S; Grady AO; Oz B; Akyurek N; Buettner R; Wolf J; Bubendorf L; Duin S; Marondel I; Heukamp LC; Timens W; Schuuring EMD; Pauwels P; Smit EF Lung Cancer; 2019 Dec; 138():13-18. PubMed ID: 31630043 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958 [TBL] [Abstract][Full Text] [Related]
13. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264 [TBL] [Abstract][Full Text] [Related]
14. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study. Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850 [TBL] [Abstract][Full Text] [Related]
15. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803 [TBL] [Abstract][Full Text] [Related]
16. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631 [TBL] [Abstract][Full Text] [Related]
17. Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. Mattsson JS; Brunnström H; Jabs V; Edlund K; Jirström K; Mindus S; la Fleur L; Pontén F; Karlsson MG; Karlsson C; Koyi H; Brandén E; Botling J; Helenius G; Micke P; Svensson MA BMC Cancer; 2016 Aug; 16():603. PubMed ID: 27495736 [TBL] [Abstract][Full Text] [Related]
18. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. Tantraworasin A; Lertprasertsuke N; Kongkarnka S; Euathrongchit J; Wannasopha Y; Saeteng S Asian Pac J Cancer Prev; 2014; 15(7):3057-63. PubMed ID: 24815447 [TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200 [TBL] [Abstract][Full Text] [Related]
20. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]